Trump administration moves to end Biden-era Medicare Part D premium subsidies

The Trump administration announced Tuesday it will let Biden-era Medicare Part D premium subsidies expire at year's end, a move affecting roughly 25 million Americans that officials say corrects an insurance-company bailout masquerading as senior relief.

CMS Administrator Dr. Mehmet Oz framed the decision as a market correction, not a benefit cut. In a post on X, Oz wrote that the subsidy program had propped up insurers rather than delivering real savings to seniors on standalone Part D prescription drug plans. The subsidies will not be renewed for 2027.

The announcement lands as the administration pushes a broader argument, one echoed across Republican healthcare policy, that pandemic-era subsidy programs inflated costs, enriched middlemen, and left taxpayers holding the bill. Whether seniors see the same math that way will depend on numbers CMS has not yet released.

Oz says most seniors will pay less than $10 more per month

On Tuesday, Oz posted two statements laying out the administration's case. The first addressed premiums directly:

"We are stabilizing the market so this bailout is no longer needed. Premiums will go up by less than $10 for most Medicare recipients, with many even seeing LOWER premiums."

His second statement shifted to the administration's broader drug-pricing agenda:

"Every Medicare beneficiary still has access to low-cost plans, and we will continue to lower prescription drug prices for every American patient, from more MFN deals to our policy giving seniors access to GLP-1s for $50 a month."

CMS published new 2027 pricing benchmarks alongside the announcement. The national average monthly bid amount, the figure insurers submit to cover a standard Part D benefit, will be $296.05. The base beneficiary premium, the portion seniors actually pay, will be $41.33. The agency said it expects to release more detailed cost information in mid- to late-September.

What CMS did not publish Tuesday was a side-by-side comparison showing what enrollees pay now under the subsidy and what they will pay without it. That gap is the number that matters most to the roughly 25 million Americans on standalone Part D plans, a figure The Hill cited from Reuters. Until September, seniors and those with disabilities will have Oz's word that the increase stays under $10 for most, but not the plan-level detail to verify it.

Biden built the subsidy; the administration calls it an insurer windfall

The premium subsidy program grew out of the Biden-era restructuring of Medicare Part D. That restructuring also created a $2,000 annual cap on out-of-pocket prescription drug spending and gave Medicare authority to negotiate prices on certain high-cost drugs. The subsidy component was designed to hold down monthly premiums as those changes took effect.

The Trump administration's core allegation is straightforward: the subsidies benefited insurance companies more than the enrollees they were supposed to help. CMS offered no independent audit or data to support that claim in Tuesday's announcement, but the argument fits a pattern conservatives have pressed for years, that government premium supports function as pass-throughs to insurers, not as genuine cost relief.

That pattern extends well beyond Medicare. Conservative policy groups have made the same case against enhanced Affordable Care Act subsidies, which became a flashpoint during the recent government shutdown fight. The Heritage Foundation's research arm and other conservative organizations argued that Biden's COVID-era ACA subsidy enhancements shifted premium costs from enrollees to taxpayers and brought more people into the subsidized market, driving up costs rather than lowering them. House Ways and Means Committee Chair Jason Smith pointed out that ObamaCare marketplace premiums have risen 80 percent since the program launched a decade ago.

The logic in both cases is the same: when the government writes checks to cover premiums, insurers raise prices to capture the subsidy, and the underlying cost of coverage never comes down. Brittany Madni of the Employment Policies Institute put it bluntly during the shutdown debate: "The supersized COVID credit subsidies aren't reducing prices whatsoever. They're just adding funds to the insurance revenues."

Medicaid, Medicare, and a broader Republican bet on restructuring

The Part D subsidy decision does not exist in isolation. It arrives weeks after the Senate passed the One Big Beautiful Bill Act on July 1, a sweeping legislative package that included roughly $1 trillion in Medicaid spending reductions over ten years, according to the Congressional Budget Office. Those Medicaid reforms, work requirements for able-bodied adults, income verification mandates, and restrictions on immigrant eligibility, drew fierce Democratic opposition and nearly split the Republican caucus.

Sen. Mike Crapo of Idaho, who shepherded the bill through the upper chamber, acknowledged the difficulty. "It was probably the hardest thing to get us to the final 50 votes," Crapo told the Washington Examiner, "and the reason is because the attack on that was, I think, so overstated and wrongly presented in the media." Rep. Brett Guthrie of Kentucky pushed back on the "cuts" label: "People think there were just cuts to Medicaid. It's not accurate at all. Medicaid still grows."

Democrats have already sued to block the administration's Medicaid work requirements, with twenty-five state attorneys general filing suit. The Part D subsidy expiration gives them another line of attack heading into the midterms, and they will use it.

But the administration's bet is that voters will eventually see the difference between a subsidy that lowers your bill and a subsidy that raises the sticker price while hiding the increase behind a government check. That distinction is real, even if it is hard to explain on a campaign mailer.

Open questions seniors deserve answered before September

Several critical details remain unresolved. CMS has not explained the precise mechanism ending the subsidy, whether it expires automatically under existing regulatory authority, requires a new rule, or involves executive action. The agency has not clarified whether the $2,000 annual out-of-pocket cap and Medicare's drug price negotiation authority will also be affected, or whether only the premium subsidy component is being removed.

Enrollees do not yet know whether they will need to re-enroll in new plans, whether they will be transitioned automatically, or whether any coverage gaps could result. And the current monthly premium under the subsidy, the baseline number needed to calculate the real-dollar impact on any individual senior, was not included in the announcement.

Meanwhile, the Democratic Party continues to fracture over its own healthcare messaging and internal priorities. Elizabeth Warren's public break with Chuck Schumer over the Michigan Senate primary underscored divisions within the caucus about whether to run on defending Biden-era programs or push further left. Even some prominent liberal voices have acknowledged that not every Trump-era policy deserves reflexive opposition, The View's Sunny Hostin recently broke with her co-hosts to praise certain Trump fertility and savings policies as genuinely beneficial.

None of that resolves the central question facing 25 million Part D enrollees: will the end of this subsidy mean a modest, manageable premium increase, or a hit that lands hardest on seniors living on fixed incomes?

Oz's $10 claim needs receipts by September

Dr. Oz's promise that most seniors will see increases under $10 is the administration's load-bearing number. If the September cost release confirms it, the decision will look like sound fiscal housekeeping, stripping away a subsidy that padded insurer margins while barely moving the needle on what seniors actually paid. If the numbers come in higher, or if certain regions and plan types see sharply steeper premiums, the political cost will be immediate and personal. Medicare enrollees vote.

The administration has earned some credibility on drug pricing by pushing GLP-1 access at $50 a month and pursuing most-favored-nation pricing deals. Those are tangible, consumer-facing moves. But credibility on pricing does not automatically extend to credibility on premium projections, especially when the detailed data is still months away.

For now, the administration is asking seniors to trust that ending a subsidy will not raise their costs in any meaningful way. That is a reasonable ask only if CMS delivers the numbers to back it up, promptly, transparently, and at the plan level where real people make real decisions.

Taxpayers deserve a healthcare system that lowers actual costs, not one that launders subsidies through insurers and calls it compassion. If this move delivers on that promise, it is long overdue. If it doesn't, the people who built their retirements around those premiums will remember who changed the deal.